Memantine combined with an acetyl cholinesterase inhibitor - Hope for the future?

Chris Fox, Ian D. Maidment, Malaz Boustani, Cornelius Katona

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Memantine and cholinesterase inhibitors (ChEI) have distinct pharmacological actions, and interest in the use of combination therapy for Alzheimer's disease (AD) is increasing. Objective: To assess the available data on the use of memantine-ChEI combination and to develop evidence-based recommendations. Method: A systematic literature review with detailed discussion of the current evidence base. Results: Available data are limited: five studies of which two were randomized, double-blind, placebo-controlled trials. One study indicated that memantine-ChEI combination is not significantly more effective than placebo-ChEI in mild to moderate AD, but data were published in abstract and poster form only. A second study indicated that the memantine-ChEI combination is significantly more effective than placebo-ChEI in moderate to severe AD. The calculated effect sizes of 0.36 on cognition and 0.12 on function, which were the primary outcomes, were small, indicating a clinically minimal effect on cognition and no effect on function. No data are available on whether combination treatment is more effective than memantine monotherapy. Conclusion: The available data do not justify the use of combination therapy. Future studies should include three arms (memantine-placebo, placebo-ChEI, and memantine-ChEI), be of an adequate size and duration, and use pragmatic measures. Clinicians should have full access to data from any future trials.

Original languageEnglish
Pages (from-to)121-125
Number of pages5
JournalNeuropsychiatric Disease and Treatment
Volume2
Issue number2
DOIs
StatePublished - 2006

Fingerprint

Memantine
Cholinesterase Inhibitors
Placebos
Alzheimer Disease
Cognition
Posters
Therapeutics
Pharmacology

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitors
  • Combination
  • Memantine
  • Open-label studies
  • Randomised control studies

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Memantine combined with an acetyl cholinesterase inhibitor - Hope for the future? / Fox, Chris; Maidment, Ian D.; Boustani, Malaz; Katona, Cornelius.

In: Neuropsychiatric Disease and Treatment, Vol. 2, No. 2, 2006, p. 121-125.

Research output: Contribution to journalArticle

Fox, Chris ; Maidment, Ian D. ; Boustani, Malaz ; Katona, Cornelius. / Memantine combined with an acetyl cholinesterase inhibitor - Hope for the future?. In: Neuropsychiatric Disease and Treatment. 2006 ; Vol. 2, No. 2. pp. 121-125.
@article{ef63f4ad16ae43b98759fd463180ad0b,
title = "Memantine combined with an acetyl cholinesterase inhibitor - Hope for the future?",
abstract = "Background: Memantine and cholinesterase inhibitors (ChEI) have distinct pharmacological actions, and interest in the use of combination therapy for Alzheimer's disease (AD) is increasing. Objective: To assess the available data on the use of memantine-ChEI combination and to develop evidence-based recommendations. Method: A systematic literature review with detailed discussion of the current evidence base. Results: Available data are limited: five studies of which two were randomized, double-blind, placebo-controlled trials. One study indicated that memantine-ChEI combination is not significantly more effective than placebo-ChEI in mild to moderate AD, but data were published in abstract and poster form only. A second study indicated that the memantine-ChEI combination is significantly more effective than placebo-ChEI in moderate to severe AD. The calculated effect sizes of 0.36 on cognition and 0.12 on function, which were the primary outcomes, were small, indicating a clinically minimal effect on cognition and no effect on function. No data are available on whether combination treatment is more effective than memantine monotherapy. Conclusion: The available data do not justify the use of combination therapy. Future studies should include three arms (memantine-placebo, placebo-ChEI, and memantine-ChEI), be of an adequate size and duration, and use pragmatic measures. Clinicians should have full access to data from any future trials.",
keywords = "Alzheimer's disease, Cholinesterase inhibitors, Combination, Memantine, Open-label studies, Randomised control studies",
author = "Chris Fox and Maidment, {Ian D.} and Malaz Boustani and Cornelius Katona",
year = "2006",
doi = "10.2147/nedt.2006.2.2.121",
language = "English",
volume = "2",
pages = "121--125",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",
number = "2",

}

TY - JOUR

T1 - Memantine combined with an acetyl cholinesterase inhibitor - Hope for the future?

AU - Fox, Chris

AU - Maidment, Ian D.

AU - Boustani, Malaz

AU - Katona, Cornelius

PY - 2006

Y1 - 2006

N2 - Background: Memantine and cholinesterase inhibitors (ChEI) have distinct pharmacological actions, and interest in the use of combination therapy for Alzheimer's disease (AD) is increasing. Objective: To assess the available data on the use of memantine-ChEI combination and to develop evidence-based recommendations. Method: A systematic literature review with detailed discussion of the current evidence base. Results: Available data are limited: five studies of which two were randomized, double-blind, placebo-controlled trials. One study indicated that memantine-ChEI combination is not significantly more effective than placebo-ChEI in mild to moderate AD, but data were published in abstract and poster form only. A second study indicated that the memantine-ChEI combination is significantly more effective than placebo-ChEI in moderate to severe AD. The calculated effect sizes of 0.36 on cognition and 0.12 on function, which were the primary outcomes, were small, indicating a clinically minimal effect on cognition and no effect on function. No data are available on whether combination treatment is more effective than memantine monotherapy. Conclusion: The available data do not justify the use of combination therapy. Future studies should include three arms (memantine-placebo, placebo-ChEI, and memantine-ChEI), be of an adequate size and duration, and use pragmatic measures. Clinicians should have full access to data from any future trials.

AB - Background: Memantine and cholinesterase inhibitors (ChEI) have distinct pharmacological actions, and interest in the use of combination therapy for Alzheimer's disease (AD) is increasing. Objective: To assess the available data on the use of memantine-ChEI combination and to develop evidence-based recommendations. Method: A systematic literature review with detailed discussion of the current evidence base. Results: Available data are limited: five studies of which two were randomized, double-blind, placebo-controlled trials. One study indicated that memantine-ChEI combination is not significantly more effective than placebo-ChEI in mild to moderate AD, but data were published in abstract and poster form only. A second study indicated that the memantine-ChEI combination is significantly more effective than placebo-ChEI in moderate to severe AD. The calculated effect sizes of 0.36 on cognition and 0.12 on function, which were the primary outcomes, were small, indicating a clinically minimal effect on cognition and no effect on function. No data are available on whether combination treatment is more effective than memantine monotherapy. Conclusion: The available data do not justify the use of combination therapy. Future studies should include three arms (memantine-placebo, placebo-ChEI, and memantine-ChEI), be of an adequate size and duration, and use pragmatic measures. Clinicians should have full access to data from any future trials.

KW - Alzheimer's disease

KW - Cholinesterase inhibitors

KW - Combination

KW - Memantine

KW - Open-label studies

KW - Randomised control studies

UR - http://www.scopus.com/inward/record.url?scp=33745910537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745910537&partnerID=8YFLogxK

U2 - 10.2147/nedt.2006.2.2.121

DO - 10.2147/nedt.2006.2.2.121

M3 - Article

VL - 2

SP - 121

EP - 125

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

IS - 2

ER -